60 Minutes Sold a Gene-Therapy Miracle Without Following the Money — or the Medical Evidence
The most consequential weakness in this investigation is that it asks who should pay millions for genetic medicine without adequately establishing what those medicines are worth, how their prices are calculated, or how much evidence supports their claimed benefits. Worse, its treatment of Elevidys omits a major regulatory development that had already occurred before the programme was published.
The FDA's warning deserved more than a passing mention
60 Minutes acknowledges that Elevidys produced mixed clinical results and that two patients died of liver failure. But the programme was published on December 14, 2025, one month after the FDA imposed a boxed warning, its strongest safety warning, following fatal liver failures in non-ambulatory patients.
The FDA also restricted the approved indication to ambulatory patients aged four and older. This was not a minor technical update: it changed which children could receive the treatment. The programme needed to explain that development and its implications for the families being asked to accept a multimillion-dollar therapy.
FDA+2
Maisie's insurer had a documented reason for refusing treatment. 60 Minutes left it out.
This is the report's most consequential omission. In July 2019, local station KJCT published details from Rocky Mountain Health Plans' actual denial letter: the insurer said the oldest child in the supporting treatment data was 5.9 months old and that there was insufficient evidence to initiate treatment after six months. It also said Maisie's existing Spinraza treatment was slowing the disease.
https\://www.kjct8.com+1
Maisie was 19 months old. The insurer's restriction was narrower than the FDA's under-two approval, and its decision was ultimately overturned on appeal. That does not establish that the refusal was justified, but it establishes that the dispute involved a clinical-evidence question, not simply a company deciding that a child's life was worth less than $2 million.
https\://www.kjct8.com+1
60 Minutes never identifies Rocky Mountain Health Plans, presents the denial letter, explains the age restriction or gives the insurer's response. It lets CG Green's accusation that the insurer was banking on her daughter's death carry the explanation.
The missing history is equally important: Maisie was already receiving Spinraza, a treatment that her mother acknowledged was slowing disease progression, although it was not stopping it. The programme presents the choice almost entirely as Zolgensma or death.
https\://www.kjct8.com+1
The family story was more complicated than the broadcast suggested
Maisie's campaign involved more than a confrontation with an insurance board. More than 700 volunteers organised a two-month campaign through a group called Maisie's Army, contacting insurers and media outlets; the group subsequently helped other families obtain treatment.
STAT
That is a more revealing account of the healthcare system: access to a newly approved treatment could depend on whether a family could mobilise hundreds of people, generate publicity and sustain an appeal before a child's disease progressed.
The $2 million price was never independently tested
Zolgensma is made by Novartis. Elevidys is made by Sarepta. Yet 60 Minutes interviews Sarepta CEO Doug Ingram to explain why gene therapies cost millions, without interviewing Novartis about the price of the medicine at the centre of its opening story.
There was an independent assessment available. In 2019, the Institute for Clinical and Economic Review (ICER) concluded that Zolgensma offered substantial health benefits for children with infantile-onset SMA, but estimated a value-based price of $310,000–$900,000 under conventional cost-effectiveness thresholds. An alternative assessment based on life-years gained produced a range of $710,000–$1.5 million. Novartis's wholesale acquisition price was $2.125 million. ICER acknowledged that ultra-rare diseases justify broader considerations beyond conventional pricing thresholds, but the difference deserved examination.
ICER+1
Novartis had also developed payment arrangements specifically to address affordability. At launch, it announced five-year instalment payments and outcomes-based agreements, under which some payment depended on continued treatment performance. The company said more than 15 payers were in advanced discussions, with some agreements reached in principle.
Novartis United States of America
These arrangements do not establish that Rocky Mountain Health Plans could have used them or that they would have resolved Maisie's coverage dispute. But why did 60 Minutes never ask? It could have examined whether the available payment arrangements were offered, what Medicaid actually paid, and whether the manufacturer's list price reflected the medicine's independently assessed value.
Instead, it substitutes one drugmaker's explanation for another's pricing decision.
Ingram's $3 billion story has a missing financial partner
Ingram told viewers that developing Elevidys took 18 years and approximately $3 billion. The programme accepts that figure without asking for a financial breakdown, examining company accounts or investigating who else financed development.
Sarepta's own SEC filings reveal a substantial partnership with Roche. In February 2020, Roche paid approximately $1.2 billion upfront under a broader collaboration agreement involving Elevidys and other products. Of that amount, $348.7 million was allocated to a combined obligation involving Elevidys intellectual property, development services and manufacturing; $485 million was allocated to options on other products, and $312.1 million to Sarepta shares.
SEC
The agreement also made Sarepta eligible for up to $1.7 billion in Elevidys development, regulatory and sales milestone payments, plus royalties. Roche shared costs under the joint global development plan and assumed responsibility for development costs specific to territories outside the United States.
SEC
This does not disprove Ingram's $3 billion figure. It does mean that the audience should not be left with the impression that Sarepta independently financed the entire undertaking and must recover every dollar through American patients.
The company's accounting raises another question. Sarepta explicitly states that significant internal research and development expenses are not allocated to individual projects. Its reported direct SRP-9001 development expenses were approximately $307.6 million in 2024 and $234.6 million in 2025. Meanwhile, Elevidys generated net product revenue of approximately $820.8 million in 2024 and $898.7 million in 2025. Revenue is not profit, and annual project expenses are not cumulative lifetime development costs. But the public accounts do not independently establish the $3 billion figure.
SEC+1
I would have asked Ingram to explain exactly what the $3 billion includes, how much Roche financed, how much has been recovered, and what profit margin the company expects at $3.2 million per treatment.
60 Minutes asked none of these questions.
Elevidys's clinical record deserved numbers, not the word "mixed"
The programme says Elevidys received FDA approval despite mixed results. That is true, but it conceals the most important clinical finding.
In the phase 3 EMBARK trial, the primary measure of motor-function improvement showed an average increase of 2.57 points among treated patients, compared with 1.92 points in the placebo group. The difference was 0.65 points on a 34-point scale and was not statistically significant (P=0.2441). Some secondary measures favoured treatment.
Nature Medicine+1
The FDA expanded approval in June 2024, explaining that it considered the secondary and exploratory results compelling despite the failure to meet the primary endpoint. That was the American regulator's decision.
FDA+1
But there was another major regulatory development before the broadcast.
In July 2025, the European Medicines Agency recommended refusing marketing authorisation. Its assessment found no statistically significant improvement in movement ability and no established relationship between production of the shortened dystrophin protein and improved physical function.
European Medicines Agency (EMA)
This does not establish that the FDA was wrong or that Elevidys provides no benefit. It establishes a serious disagreement between regulators over the available evidence.
The programme gives viewers neither the actual trial result nor the European decision. Instead, it presents a boy whose parents say he is thriving and stronger. An individual success story cannot resolve a disputed clinical evidence base.
Mosaic's financial problem was real, but the broadcast left out the financial context
Bloomberg's September 2024 investigation provided figures that 60 Minutes should have included.
Mosaic Life Care reportedly set aside approximately $56 million annually for healthcare costs covering 4,700 employees. The $4.2 million required to treat the Reed twins would therefore represent almost 8% of that annual budget. This is a substantial financial burden, not an imaginary problem.
Medical Xpress
But the programme never establishes how Mike Poore arrived at his claim that employee premiums would rise $125 per month. It does not provide the number of covered employees, the actuarial calculation or the plan's arrangements for catastrophic claims.
KFF reported that 63% of covered workers were enrolled in self-funded plans in 2024. It also found that 75% of covered workers in self-funded plans at large firms had stop-loss insurance, which can protect employers against unusually expensive claims. This does not establish that Mosaic had such protection; it makes the absence of that question important.
KFF+1
There is another missing detail: Poore himself blamed Novartis for charging an exorbitant price, according to Bloomberg. The programme does not explore that disagreement with the manufacturer. Instead, Gruber concludes that there are no bad guys.
The actual dispute was less comfortable than that.
The chronology of the twins' treatment also deserves clarification. Bloomberg reported that a state lawmaker helped expedite their Medicaid coverage and that the family had secured coverage by the time Mosaic announced its philanthropic fund. The twins received their first Zolgensma infusion on May 14, 2024, paid for by Medicaid.
Medical Xpress
Mosaic subsequently announced a $3.4 million fund, comprising a $1.5 million contribution from the hospital and a $1.9 million anonymous donation. The family had already been securing coverage before that announcement. The available reporting does not establish that this fund paid for the twins' treatment.
KRDO
60 Minutes compresses these events into a sequence in which Poore appeals for help and Medicaid eventually pays. It never explains precisely who secured the coverage, when it was secured, or what role the philanthropic fund actually played.
Those distinctions matter when judging the CEO's actions and the employer's responsibility.
A government payment model already existed
Gruber's proposed solution is government support and negotiated drug prices. Yet the federal government had already begun testing precisely that approach.
In July 2025, CMS announced its Cell and Gene Therapy Access Model, involving 33 states, the District of Columbia and Puerto Rico. The programme covers approximately 84% of Medicaid beneficiaries with sickle cell disease in participating jurisdictions and uses federally negotiated outcomes-based agreements with manufacturers. States can receive rebates tied to treatment outcomes.
CMS+1
The initial programme covers sickle cell disease, not SMA or Duchenne muscular dystrophy. It is not a complete solution to the cases featured by 60 Minutes.
But it is a concrete example of government-negotiated pricing and shared financial risk already being put into practice. The broadcast could have examined its early implementation, limitations and potential expansion instead of leaving the audience with a general prediction that government intervention will eventually be necessary.
The distinction is important: the problem is not that nobody has developed possible payment mechanisms. It is that existing mechanisms remain limited in scope and have not yet solved the financing problems across all genetic diseases.
The verdict
Maisie's survival is real. The financial pressure on Mosaic is real. The extraordinary cost of developing genetic medicines is also real.
But 60 Minutes does not adequately establish why Maisie's insurer initially refused treatment, whether Zolgensma's price was justified, how Sarepta's development costs were financed, or how strong the clinical evidence for Elevidys actually was.
It gives the pharmaceutical manufacturer a platform to defend its price, the mother a platform to describe her suffering, and the employer a platform to describe its financial predicament. It does not do enough of the investigative work connecting those accounts.
The most troubling omission is the absence of documentary scrutiny. The original denial letter, the pharmaceutical agreements, the independent price assessment, the clinical trial results and the regulatory decisions were all relevant to the questions the programme claimed to investigate.
Instead, viewers are encouraged to accept a morality play in which nobody is responsible because the system has changed.
I reject that conclusion as premature.
Drugmakers set prices. Employers decide what their plans cover. Administrators apply coverage rules. Regulators decide what evidence is sufficient for approval. Governments determine how public money is spent.
These are identifiable decisions made by identifiable institutions. They deserve examination, not a convenient declaration that there are no bad guys.
60 Minutes delivered an emotionally powerful story about medical breakthroughs. It did not deliver an equally rigorous investigation into the money, evidence and institutional decisions determining who gets them.
References
1. Breakthrough genetic therapies can save lives, but many cost millions for single dose — CBS News, December 14, 2025. The original transcript establishes precisely what 60 Minutes reported and what it left unexplored.
2. Grand Junction baby denied life-saving coverage from insurance — KJCT, July 18, 2019. Contains Rocky Mountain Health Plans' response and the actual age-related reasoning quoted from Maisie's denial letter.
3. Maisie's Army: How a grassroots group is mobilizing to help toddlers access a lifesaving drug — STAT, August 20, 2019. Documents the 700-volunteer campaign, its two-month effort and the insurer's eventual reversal.
4. ICER's Assessment Finds Spinraza and Zolgensma Provide Substantial Health Benefits — Institute for Clinical and Economic Review, February 22, 2019. Provides independent clinical and value-based pricing assessments for the two SMA treatments.
5. AveXis Announces Innovative Zolgensma Gene Therapy Access Programs — Novartis/AveXis, May 24, 2019. Documents the $2.125 million launch price, five-year payment arrangements and outcomes-based agreements.
6. Sarepta Therapeutics 2025 Form 10-K — U.S. Securities and Exchange Commission, 2026. Provides the Roche financing agreement, development-cost disclosures, milestone arrangements, royalties and Elevidys sales figures.
7. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial — Nature Medicine, 2024. Provides the actual primary and secondary clinical trial results, including the statistically insignificant primary endpoint.
8. Elevidys European Public Assessment Report — European Medicines Agency, July 25, 2025; updated October 20, 2025. Explains why European regulators refused marketing authorisation.
9. FDA Approves New Safety Warning and Revised Indication for Elevidys — U.S. Food and Drug Administration, November 14, 2025. Documents the boxed warning, fatal liver injuries and removal of non-ambulatory patients from the approved indication.
10. 2024 Employer Health Benefits Survey — KFF, 2024. Establishes the prevalence of self-funded employer plans and the availability of stop-loss insurance.
11. Cures for rare diseases now exist: Employers don't want to pay — Gerry Smith, Bloomberg News, September 9, 2024. Provides Mosaic's healthcare budget, Poore's criticism of Novartis and the chronology of Medicaid coverage for the Reed twins.
12. Family says coverage for specialized treatment for twins obtained before hospital announcement of specialized fund — KRDO/KMBC, May 6, 2024. Documents the $3.4 million philanthropic fund and the family's account of when treatment coverage was secured.
13. CMS Expands Access to Lifesaving Gene Therapies Through Innovative State Agreements — Centers for Medicare & Medicaid Services, July 15, 2025. Documents the federal Cell and Gene Therapy Access Model and its negotiated outcomes-based payment arrangements.